Abcalis Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 6

Abcalis General Information

Description

Developer of recombinant antibodies intended for diagnostic and research applications. The company generates and produces sequence-defined, animal-free antibodies through phage display, affinity maturation, and antibody format conversion, enabling diagnostic companies and researchers to conduct reliable tests and experiments with reproducible reagents.

Contact Information

Website
www.abcalis.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Corporate Office
  • Inhoffenstrasse 7
  • 38124 Braunschweig
  • Germany
+49 0531
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Vertical(s)
Corporate Office
  • Inhoffenstrasse 7
  • 38124 Braunschweig
  • Germany
+49 0531

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Abcalis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator Completed Generating Revenue
5. Grant 17-Nov-2022 Completed Generating Revenue
4. Grant 30-Mar-2022 Completed Generating Revenue
3. Accelerator/Incubator 22-Oct-2021 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. University Spin-Out 01-Jan-2019 Completed Generating Revenue
To view Abcalis’s complete valuation and funding history, request access »

Abcalis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Abcalis Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Braunschweigische Landessparkasse Corporation
European Coalition to End Animal Experiments Impact Investing
SNIC Accelerator Accelerator/Incubator
Technische Universität Braunschweig University
German Accelerator Accelerator/Incubator
You’re viewing 5 of 6 investors. Get the full list »

Abcalis FAQs

  • When was Abcalis founded?

    Abcalis was founded in 2019.

  • Where is Abcalis headquartered?

    Abcalis is headquartered in Braunschweig, Germany.

  • What is the size of Abcalis?

    Abcalis has 7 total employees.

  • What industry is Abcalis in?

    Abcalis’s primary industry is Biotechnology.

  • Is Abcalis a private or public company?

    Abcalis is a Private company.

  • What is Abcalis’s current revenue?

    The current revenue for Abcalis is .

  • Who are Abcalis’s investors?

    Braunschweigische Landessparkasse, European Coalition to End Animal Experiments, SNIC Accelerator, Technische Universität Braunschweig, and German Accelerator are 5 of 6 investors who have invested in Abcalis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process